LLY vs RDNT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
RDNT exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While revenue growth remains positive at 14.8%, the company is struggling with negative profit margins (-0.91%) and a catastrophic collapse in year-over-year EPS growth (-104.5%). There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling and negative earnings surprises. The valuation is aggressive, with a forward P/E of 58.82 that is not supported by current profitability.
Compare Another Pair
Related Comparisons
LLY vs RDNT: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and RadNet, Inc. (RDNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.